{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:17:49Z","timestamp":1792801069318,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"name":"University of Texas MD Anderson SPORE","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}]},{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Several menin inhibitors are in development targeting menin dependent leukemias, however available preclinical results show variable level of activity. We report the phase 1 portion (to establish a recommended phase 2 dose [RP2D]) and pharmacokinetic analysis of a phase 1\/2 first-in-human clinical trial of DS-1594b menin inhibitor. Eligible patients included adults (\u2265\u200918 years of age) with relapsed\/refractory (R\/R) acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) including but not restricted to those with\n                    <jats:italic>KMT2A<\/jats:italic>\n                    -rearrangement (r) or\n                    <jats:italic>NPM1<\/jats:italic>\n                    mutation. Seventeen patients at a median of age 56 years (range, 19\u201382 years) were treated, 15 (88%) had R\/R AML, and 2 (12%) had R\/R B-ALL; 9 (53%) had a\n                    <jats:italic>KMT2A<\/jats:italic>\n                    -r but none had an\n                    <jats:italic>NPM1<\/jats:italic>\n                    mutation. The median prior lines of therapy was 3 (range 1\u20138) and 5 patients (29%) had received prior menin inhibitors. Five dose escalation cohorts were evaluated; no RP2D was established, and the trial was stopped at phase 1 due to a decision by supporting company due to lack of efficacy at studied dose levels and portfolio realignment. Differentiation syndrome (DS) was seen in 5 patients (29%); 2 in cohort 1 (70\u00a0mg twice daily,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20094) 1 each had grade 1 and grade 4 DS, 3 patients in cohort 2 (50\u00a0mg twice daily\/100\u00a0mg daily,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20094) of whom 2 had grade 2 and 1 patient had grade 3 DS (considered as dose limiting toxicity). No DS was noted at cohort 3 (20\u00a0mg\/day), and in subsequent dose-escalation cohorts (cohorts 4 and 5) a lead-in ramp-up dosing starting at 20\u00a0mg\/day was instituted to improve tolerability. Other relevant treatment emergent adverse events of grade\u2009\u2265\u20093 included infections; pneumonia and febrile neutropenia in 7 patients each (41%), and sepsis in 6 patients (35%). No study drug related deaths were noted. No patient achieved a response, however 4 patients (23%) had\u2009&gt;\u200925% bone marrow blast reduction. Pharmacokinetic analysis showed DS-1594b reached maximum concentration approximately in 2\u00a0h with total exposure increasing with escalating doses and reached stead-state by Cycle 1 Day 8. DS-1594b showed limited efficacy at the doses tested but appeared safe with a lead-in dosing approach.\n                  <\/jats:p>","DOI":"10.1186\/s13045-025-01757-4","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T18:46:22Z","timestamp":1764269182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A phase 1\/2 study of DS-1594 menin inhibitor in relapsed\/refractory acute leukemias"],"prefix":"10.1186","volume":"18","author":[{"given":"Jayastu","family":"Senapati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indraneel","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joie","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein A.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narasimha M.","family":"Midde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Noyalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek E.","family":"Mires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianchun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"issue":"7","key":"1757_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35806","volume":"131","author":"J Senapati","year":"2025","unstructured":"Senapati J, Kadia TM, Daver NG, et al. Therapeutic horizon of acute myeloid leukemia: success, optimism, and challenges. Cancer. 2025;131(7):e35806. https:\/\/doi.org\/10.1002\/cncr.35806.","journal-title":"Cancer"},{"issue":"10393","key":"1757_CR2","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/s0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401(10393):2073\u201386. https:\/\/doi.org\/10.1016\/s0140-6736(23)00108-3.","journal-title":"Lancet"},{"issue":"12","key":"1757_CR3","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood.2024024009","volume":"145","author":"AH Wei","year":"2025","unstructured":"Wei AH, Loo S, Daver N. How I treat patients with AML using azacitidine and venetoclax. Blood. 2025;145(12):1237\u201350. https:\/\/doi.org\/10.1182\/blood.2024024009.","journal-title":"Blood"},{"issue":"6","key":"1757_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/blood.2024026232","volume":"145","author":"G Huls","year":"2025","unstructured":"Huls G, Woolthuis CM, Schuringa JJ. Menin inhibitors in the treatment of acute myeloid leukemia. Blood. 2025;145(6):561\u20136. https:\/\/doi.org\/10.1182\/blood.2024026232.","journal-title":"Blood"},{"issue":"6","key":"1757_CR5","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","volume":"36","author":"AV Krivtsov","year":"2019","unstructured":"Krivtsov AV, Evans K, Gadrey JY, et al. A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-Rearranged leukemia. Cancer Cell. 2019;36(6):660\u2013e67311. https:\/\/doi.org\/10.1016\/j.ccell.2019.11.001. (In eng).","journal-title":"Cancer Cell"},{"issue":"6","key":"1757_CR6","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1182\/blood.2021012806","volume":"139","author":"EB Heikamp","year":"2022","unstructured":"Heikamp EB, Henrich JA, Perner F, et al. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood. 2022;139(6):894\u2013906. https:\/\/doi.org\/10.1182\/blood.2021012806.","journal-title":"Blood"},{"issue":"1","key":"1757_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/jco.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa GC, Aldoss I, Thirman MJ, et al. Menin Inhibition with revumenib for <\u2009i\u2009>\u2009KMT2A-Rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2025;43(1):75\u201384. https:\/\/doi.org\/10.1200\/jco.24.00826.","journal-title":"J Clin Oncol"},{"key":"1757_CR8","doi-asserted-by":"publisher","unstructured":"Issa GC, Cuglievan B, Daver N, Blood et al. 2024;144(Supplement 1):216\u2013216. https:\/\/doi.org\/10.1182\/blood-2024-204375","DOI":"10.1182\/blood-2024-204375"},{"issue":"7954","key":"1757_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","volume":"615","author":"F Perner","year":"2023","unstructured":"Perner F, Stein EM, Wenge DV, et al. MEN1 mutations mediate clinical resistance to Menin inhibition. Nature. 2023;615(7954):913\u20139. https:\/\/doi.org\/10.1038\/s41586-023-05755-9.","journal-title":"Nature"},{"issue":"11","key":"1757_CR10","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1182\/blood.2023022480","volume":"144","author":"MC Kwon","year":"2024","unstructured":"Kwon MC, Thuring JW, Querolle O, et al. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Blood. 2024;144(11):1206\u201320. https:\/\/doi.org\/10.1182\/blood.2023022480.","journal-title":"Blood"},{"issue":"10","key":"1757_CR11","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","volume":"25","author":"ES Wang","year":"2024","unstructured":"Wang ES, Issa GC, Erba HP, et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol. 2024;25(10):1310\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(24)00386-3.","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"1757_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1182\/blood-2024-194827","volume":"144","author":"JF Zeidner","year":"2024","unstructured":"Zeidner JF, Yuda J, Watts JM, et al. Phase 1 results: First-in-human phase 1\/2 study of the Menin-MLL inhibitor Enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. Blood. 2024;144(Supplement 1):213\u2013213. https:\/\/doi.org\/10.1182\/blood-2024-194827.","journal-title":"Blood"},{"issue":"9","key":"1757_CR13","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","volume":"35","author":"GC Issa","year":"2021","unstructured":"Issa GC, Ravandi F, DiNardo CD, Jabbour E, Kantarjian HM, Andreeff M. Therapeutic implications of Menin inhibition in acute leukemias. Leukemia. 2021;35(9):2482\u201395. https:\/\/doi.org\/10.1038\/s41375-021-01309-y.","journal-title":"Leukemia"},{"issue":"9","key":"1757_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00557-6","volume":"11","author":"GC Issa","year":"2021","unstructured":"Issa GC, Zarka J, Sasaki K, et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021;11(9):162. https:\/\/doi.org\/10.1038\/s41408-021-00557-6.","journal-title":"Blood Cancer J"},{"issue":"6","key":"1757_CR15","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/bloodadvances.2022008316","volume":"7","author":"GC Issa","year":"2023","unstructured":"Issa GC, Bidikian A, Venugopal S, et al. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv. 2023;7(6):933\u201342. https:\/\/doi.org\/10.1182\/bloodadvances.2022008316.","journal-title":"Blood Adv"},{"issue":"9","key":"1757_CR16","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1038\/s41375-024-02333-4","volume":"38","author":"A Hern\u00e1ndez-S\u00e1nchez","year":"2024","unstructured":"Hern\u00e1ndez-S\u00e1nchez A, Gonz\u00e1lez T, Sobas M, et al. Rearrangements involving 11q23.3\/KMT2A in adult AML: mutational landscape and prognostic implications \u2013 a HARMONY study. Leukemia. 2024;38(9):1929\u201337. https:\/\/doi.org\/10.1038\/s41375-024-02333-4.","journal-title":"Leukemia"},{"issue":"1","key":"1757_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-02877-y","volume":"23","author":"M Numata","year":"2023","unstructured":"Numata M, Haginoya N, Shiroishi M, et al. A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1. Cancer Cell Int. 2023;23(1):36. https:\/\/doi.org\/10.1186\/s12935-023-02877-y.","journal-title":"Cancer Cell Int"},{"issue":"Supplement 1","key":"1757_CR18","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1182\/blood-2022-167205","volume":"140","author":"V Ciaurro","year":"2022","unstructured":"Ciaurro V, Skwarska A, Daver N, Konopleva M. Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with venetoclax in AML cells with MLL-rearranged and NPM1 mutation. Blood. 2022;140(Supplement 1):3082\u20133. https:\/\/doi.org\/10.1182\/blood-2022-167205.","journal-title":"Blood"},{"issue":"4","key":"1757_CR19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"Blood"},{"issue":"4","key":"1757_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/sim.4780140404","volume":"14","author":"PF Thall","year":"1995","unstructured":"Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med. 1995;14(4):357\u201379. https:\/\/doi.org\/10.1002\/sim.4780140404.","journal-title":"Stat Med"},{"issue":"12","key":"1757_CR21","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1182\/blood.2024024008","volume":"145","author":"GC Issa","year":"2025","unstructured":"Issa GC, Stein EM, DiNardo CD. How i treat acute myeloid leukemia with differentiation therapy. Blood. 2025;145(12):1251\u20139. https:\/\/doi.org\/10.1182\/blood.2024024008.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1757_CR22","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1182\/blood-2024-208887","volume":"144","author":"W Bourgeois","year":"2024","unstructured":"Bourgeois W, Cutler J, Rice HE, et al. Discerning the landscape of Menin inhibitor resistance. Blood. 2024;144(Supplement 1):724\u2013724. https:\/\/doi.org\/10.1182\/blood-2024-208887.","journal-title":"Blood"},{"issue":"1","key":"1757_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00603-3","volume":"12","author":"W Fiskus","year":"2022","unstructured":"Fiskus W, Boettcher S, Daver N. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 2022;12(1):5. https:\/\/doi.org\/10.1038\/s41408-021-00603-3.","journal-title":"Blood Cancer J"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01757-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01757-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01757-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T18:46:24Z","timestamp":1764269184000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01757-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1757"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01757-4","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GCI reports personal\/consulting fees from Novartis, Sanofi, and Syndax and data and safety monitoring for Novartis outside the submitted work. TMK reports grants\/contracts from Ascentage Pharma, Bristol Myers Squibb Company, Genentech, Incyte Corporation, and Jazz Pharmaceuticals; and personal\/consulting fees from AbbVie, Agios Pharmaceuticals Inc., Daiichi Sankyo Company, Genentech, Novartis, Servier Pharmaceuticals, and Syndax outside the submitted work. CDD reports grants\/contracts and research funding from AbbVie, Astex, BeiGene, Bristol Myers Squibb Company, Foghorn, ImmuneOnc, Remix Rigel, Servier, and Schrodinger; personal\/consulting fees from AbbVie, Astellas Pharma Inc., AstraZeneca BeiGene, Bristol Myers Squibb Company, Genmab, GlaxoSmithKline, Molecular Partners, Ryvu, Schrodinger, Servier, and Stemline; honoraria from AbbVie, Astellas Pharma Inc., Bristol Myers Squibb Company, Jazz Pharmaceuticals, and Servier; support for attending meetings\/travel from Servier; and service on a Data Safety Board at Genmab outside the submitted work. NP reports grants\/contracts from the US Department of Defense; personal\/consulting fees from AbbVie, Bristol Myers Squibb Company, GSK Consulting, Immunogen, Incyte Corporation, Johnson & Johnson, Karyopharm Therapeutics, Morphosys, OPNA, Protagonist Therapeutics, Sobi, Takeda Oncology, and Total CME; and support for other professional activities from CTI BioPharma, Dan\u2019s House of Hope, Menarini Group, and Payclex outside the submitted work. NJS reports grants\/contracts and research funding from Ascentage, Astellas Pharma Inc., GlaxoSmithKline, Hemogenyx, NextCure, Novartis, Stemline Therapeutics Inc., Takeda Oncology, Vironexis and Xencor; personal\/consulting fees from Adaptive Biotechnologies, Amgen, Autolus, GlaxoSmithKline, Novartis, PFIZER CANADA INC., and Pfizer Inc.; and honoraria from Adaptive Biotechnologies, Amgen, Astellas Pharma Inc., Pfizer Inc., Sanofi, and Takeda Oncology outside the submitted work. SL reports grants\/contracts from Amgen and Astellas Pharma; personal\/consulting fees from AbbVie, AlphaSight, Aptitude Health, Arima, Blueprint Medicine, Bristol Myers Squibb Company, Caris Diagnostics, Daiichi Sankyo Company, Gerson Lehrman Group, Guidepoint, Kura Oncology, Opinion Health, Qiagen Inc., QualWorld, Recordati Rare Diseases Inc., Servier Affaires Medicales, Stemline Therapeutics Inc., Syndax, and Tempus; and owns stock in AbbVie and PureTech outside the submitted work. HAA reports research support from Ascentage, Blueprint Medicines, Genentech, Enzyme-By-Design, Genentech, GlaxoSmithKline, and Illumina; personal\/consulting or advisory fees from Cogent Biosciences and Molecular Partners; honoraria from Alamar Biotechnology and Illumina; and in-kind support from Illumina outside the submitted work. NM, NS, AN and DM are employed with Daiichi Sankyo. FR reports grants\/contracts from Bristol Myers Squibb Company and Taiho Pharmaceutical; personal\/consulting fees from Amgen, Astellas Pharma, Bristol Myers Squibb Company, Celgene Corporation, Novartis Foundation, and Taiho Pharmaceutical; and support for other professional activities from Celgene Corporation outside the submitted work. HMK reports institutional grants from AbbVie, Amgen, Ascentage, Bristol Myers Squibb Company, Daiichi Sankyo Company, Immunogen, and Novartis; personal\/consulting fees from AbbVie, Amgen, Ascentage, Ipsen Biopharmaceuticals, KAHR Medical, Novartis, Pfizer, Shenzhen Target Rx, Stemline, and Takeda Oncology outside the submitted work. NGD reports grants\/contracts from AbbVie Inc., Amgen, Astellas Pharma, Bristol Myers Squibb Company, Daiichi Sankyo Company, FATE Therapeutics, Genentech, Gilead Sciences Inc., Glycomimetics, Hanmi, ImmunoGen Inc., Kite Pharma Inc., Novimmune, Pfizer Inc., Servier Pharmaceuticals LLC, Trillium, and Trovagene; and personal\/consulting fees from AbbVie, Agios Pharmaceuticals Inc., Amgen, Arog Pharmaceuticals, Astellas Pharma, Bristol Myers Squibb Company, Celgene, Daiichi Sankyo Company, Genentech, Gilead Sciences Inc., ImmunoGen Inc., Jazz Pharmaceuticals, Kite Pharma Inc., Novartis, Pfizer Inc., Servier Pharmaceuticals LLC, Shattuck Labs, Stemline\/Menarini, Syndax, and Trillium outside the submitted work. The remaining authors disclosed no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}